Pelthos Therapeutics (PTHS)
:PTHS
PTHS Stock Chart & Stats
$22.90
--
Market closed
$22.90
--
Day’s Range― - ―
52-Week Range$9.00 - $54.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.94K
Market Cap
$76.84M
Enterprise Value$31.66M
Total Cash (Recent Filing)$18.02M
Total Debt (Recent Filing)$34.83M
Price to Earnings (P/E)―
Beta1.92
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,355,543
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit3.01
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$57.14Price Target Upside149.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market AdoptionAnalyst views strong prescriber adoption and early evidence of repeat use across dermatology and pediatric settings as validation of real patient demand that should support continued prescription growth.
Pipeline And ManufacturingAnalyst notes that adding launch‑ready topical products like Xeglyze and maintaining in‑house active ingredient manufacturing can expand the commercial portfolio, improve profitability potential, and raise barriers to competition.
Product DifferentiationAnalyst highlights that Zelsuvmi's position as the first at‑home prescription treatment for molluscum contagiosum and its favorable tolerability versus in‑office blistering options create a clear commercial advantage.
Bears Say
Commercial And Regulatory Execution RiskAnalyst identifies commercial execution, reimbursement, intellectual property and regulatory hurdles as key risks that could limit sales growth and prevent achievement of targets.
Cost Structure And LeverageAnalyst warns that higher selling and administrative expenses combined with the company's term loan increase financial obligations and can pressure margins.
Pricing And Reimbursement PressureAnalyst cautions that increasing payer contracting and higher gross‑to‑net pressures could materially reduce net revenue as product volumes scale.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $9.00 and its highest was $54.29 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $76.84M.
When is Pelthos Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pelthos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,355,543 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.14 (149.52% Upside)
$57.14 (149.52% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
315.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5808.39%
Trailing 12-Months
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
PTHS Earnings Call
Q4 2026
0:00 / 0:00
PTHS Stock 12 Month Forecast
Average Price Target
$57.14
▲(149.52% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―